<DOC>
	<DOCNO>NCT00734240</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability single multiple dos ISIS 353512 , evaluate blood concentration rate elimination ISIS 353512 blood , evaluate effectiveness ISIS 353512 lower protein blood associate inflammation .</brief_summary>
	<brief_title>Safety Tolerability Single Multiple Doses ISIS 353512 Healthy Volunteers</brief_title>
	<detailed_description>This Phase 1 , double blind , placebo-controlled , dose-escalation study conduct single center 1 ) evaluate safety tolerability single multiple dos ISIS 353512 administer intravenously subcutaneously , 2 ) evaluate pharmacokinetic profile single multiple dos ISIS 353512 administer intravenously subcutaneously , 3 ) evaluate pharmacodynamics ISIS 353512 lower constitutive level c-reactive protein healthy volunteer .</detailed_description>
	<criteria>Age 18 55 year Male female although female must postmenopausal surgically sterile In good health BMI &lt; 32 kg/m2 Give write informed consent participate study hsCRP Screening ≥ 0.50 mg/L ≤ 5.0 mg/L ( 2 measurement ≥ 2 week apart ; difference measurement ≤ 2.5 mg/L ) ( Multiple Dose Subjects , include dosetitration cohort ) Pregnant woman , nurse mother woman childbearing potential Clinically significant abnormality medical history physical examination Clinically significant ECG abnormality vital sign abnormality ( systolic blood pressure &lt; 90 mm Hg &gt; 140 mm Hg , diastolic blood pressure &lt; 50 mm Hg &gt; 90 mm Hg heat rate &lt; 50 &gt; 100 bpm ) Screening Clinically significant abnormality laboratory examination , hsCRP Clinically significant abnormality coagulation parameter Positive test HIV , TB ( PPD test ) hepatitis B C Screening History latent active tuberculosis exposure endemic area within 8 week prior PPD test Screening History positive PPD test positive PPD test result ( ≥ 5 mm ) indicate possible tuberculosis infection Fasting triglycerides &gt; 400 mg/dL Screening Malignancy ( exception basal squamous cell carcinoma skin adequately treat recurrence &gt; 1 year ) Evidence ongoing chronic inflammatory condition infection Any concurrent condition , opinion Investigator , would preclude participation study interfere compliance Regular use alcohol within 6 month prior Screening ( &gt; 14 unit alcohol per week ; 1 unit = 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ) Use soft drug ( marijuana ) within 3 month prior Screening hard drug ( cocaine , phencyclidine [ PCP ] crack ) within 1 year prior Screening , positive urine drug screen Screening Smoking &gt; 10 cigarette per day Use investigational drug participation investigational study involve small molecule 30 day prior dose participation investigational study involve biologic compound within 90 day prior dose Regularly take OTC medication and/or vitamin supplement may alter CRP , e.g. , NSAIDs , aspirin , vitamin E , fish oil , within 14 day prior Screening Receiving prescription medication , include hormone replacement therapy , statin , TNFα inhibitor , antiinflammatory immunosuppressive drug within 30 day prior Screening Immunization live attenuate vaccine one month prior dose plan vaccination course study Blood donation 50 499 mL within 30 day Screening &gt; 499 mL within 60 day Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>